Barry S. Rosenstein

Dr. Rosenstein is a Professor of Radiation Oncology and a Professor of Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai. The focus of Dr. Rosenstein’s research program for the past 25 years has been the identification of enetic/genomic markers associated with the development of adverse effects resulting from radiotherapy. In this context, he was one of the first investigators to hypothesize that possession of single nucleotide polymorphisms in certain genes may render some cancer patients more susceptible to injuries resulting from radiotherapy. Dr. Rosenstein established and co-led for 14 years the Radiogenomics Consortium (RGC), representing an international consortium currently with 240 members in 33 countries across 135 institutions. Through his efforts, Dr. Rosenstein, has been in the forefront of research in the use of big data in radiation oncology and has collaborated with investigators possessing expertise in bioinformatics and statistics to employ machine learning-based modeling approaches in radiogenomic studies.